The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling

Biomed Pharmacother. 2020 Nov:131:110785. doi: 10.1016/j.biopha.2020.110785. Epub 2020 Sep 29.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, as it affects up to 30 % of adults in Western countries. Moreover, NAFLD is also considered an independent risk factor for cardiovascular diseases. Insulin resistance and inflammation have been identified as key factors in the pathophysiology of NAFLD. Although the mechanisms associated with the development of NAFLD remain to be fully elucidated, a complex interaction between adipokines and cytokines appear to play a crucial role in the development of this condition. Adiponectin is the most common adipokine known to be inversely linked with insulin resistance, lipid accumulation, inflammation and NAFLD. Consequently, the focus has been on the use of new therapies that may enhance hepatic expression of adiponectin downstream targets or increase the serum levels of adiponectin in the treatment NAFLD. While currently used therapies show limited efficacy in this aspect, accumulating evidence suggest that various dietary polyphenols may stimulate adiponectin levels, offering potential protection against the development of insulin resistance, inflammation and NAFLD as well as associated conditions of metabolic syndrome. As such, this review provides a better understanding of the role polyphenols play in modulating adiponectin signaling to protect against NAFLD. A brief discussion on the regulation of adiponectin during disease pathophysiology is also covered to underscore the potential protective effects of polyphenols against NAFLD. Some of the prominent polyphenols described in the manuscript include aspalathin, berberine, catechins, chlorogenic acid, curcumin, genistein, piperine, quercetin, and resveratrol.

Keywords: Antioxidants; Inflammation; Insulin resistance; Lipid metabolism; Nonalcoholic fatty liver diseases; Oxidative stress.

Publication types

  • Review

MeSH terms

  • Adipokines / metabolism
  • Adiponectin / metabolism*
  • Adult
  • Animals
  • Cytokines / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / physiopathology
  • Insulin Resistance
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / physiopathology
  • Polyphenols / pharmacology*
  • Signal Transduction / drug effects

Substances

  • Adipokines
  • Adiponectin
  • Cytokines
  • Polyphenols